 Natalie Davidson
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystadenocarcinoma, Serous | 4 | 2025 | 89 | 1.410 |
Why?
| | Ovarian Neoplasms | 6 | 2025 | 595 | 1.260 |
Why?
| | Software | 2 | 2025 | 680 | 0.930 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 362 | 0.890 |
Why?
| | Journalism | 1 | 2024 | 5 | 0.840 |
Why?
| | Computational Biology | 2 | 2025 | 669 | 0.650 |
Why?
| | Computer Graphics | 1 | 2017 | 41 | 0.500 |
Why?
| | Algorithms | 2 | 2025 | 1845 | 0.410 |
Why?
| | Internet | 1 | 2017 | 689 | 0.350 |
Why?
| | Computer Simulation | 2 | 2025 | 1003 | 0.250 |
Why?
| | Neoplasm Grading | 2 | 2025 | 310 | 0.250 |
Why?
| | Sequence Analysis, RNA | 2 | 2025 | 442 | 0.230 |
Why?
| | Claudin-4 | 1 | 2025 | 18 | 0.230 |
Why?
| | Homologous Recombination | 1 | 2025 | 37 | 0.230 |
Why?
| | Tumor Escape | 1 | 2025 | 49 | 0.220 |
Why?
| | Immune Evasion | 1 | 2025 | 61 | 0.220 |
Why?
| | Genomic Instability | 1 | 2025 | 67 | 0.220 |
Why?
| | Genomics | 3 | 2025 | 825 | 0.210 |
Why?
| | Bibliometrics | 1 | 2024 | 66 | 0.200 |
Why?
| | Authorship | 1 | 2024 | 49 | 0.200 |
Why?
| | Sexism | 1 | 2024 | 68 | 0.200 |
Why?
| | Science | 1 | 2024 | 55 | 0.190 |
Why?
| | Glycine Hydroxymethyltransferase | 1 | 2022 | 16 | 0.190 |
Why?
| | Periodicals as Topic | 1 | 2024 | 209 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2022 | 440 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1321 | 0.170 |
Why?
| | Eukaryotic Initiation Factor-1 | 1 | 2018 | 3 | 0.140 |
Why?
| | Metabolomics | 1 | 2024 | 732 | 0.140 |
Why?
| | Activating Transcription Factor 4 | 1 | 2018 | 22 | 0.140 |
Why?
| | Female | 10 | 2025 | 78844 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2105 | 0.140 |
Why?
| | Proteomics | 1 | 2024 | 1188 | 0.130 |
Why?
| | ras Proteins | 1 | 2018 | 150 | 0.130 |
Why?
| | Sulfobromophthalein | 1 | 2017 | 1 | 0.130 |
Why?
| | Humans | 15 | 2025 | 145474 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1443 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 228 | 0.120 |
Why?
| | Systems Biology | 1 | 2017 | 69 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2018 | 247 | 0.120 |
Why?
| | Mice | 5 | 2025 | 18329 | 0.120 |
Why?
| | Jews | 1 | 2016 | 20 | 0.120 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 170 | 0.110 |
Why?
| | Genetics, Population | 1 | 2016 | 217 | 0.110 |
Why?
| | Linear Models | 1 | 2017 | 845 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 350 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2022 | 928 | 0.100 |
Why?
| | RNA | 1 | 2020 | 910 | 0.100 |
Why?
| | Mutation | 2 | 2025 | 4075 | 0.090 |
Why?
| | Animals | 5 | 2025 | 38030 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 734 | 0.080 |
Why?
| | Middle Aged | 4 | 2025 | 36215 | 0.080 |
Why?
| | Aged | 3 | 2025 | 26153 | 0.080 |
Why?
| | Signal Transduction | 1 | 2022 | 5216 | 0.070 |
Why?
| | Liver | 1 | 2017 | 1896 | 0.070 |
Why?
| | Male | 3 | 2025 | 72842 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3542 | 0.060 |
Why?
| | Transcriptome | 2 | 2024 | 1038 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2906 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 133 | 0.050 |
Why?
| | Peptide Elongation Factor 2 | 1 | 2022 | 5 | 0.050 |
Why?
| | Cycloheximide | 1 | 2022 | 42 | 0.050 |
Why?
| | Dactinomycin | 1 | 2022 | 23 | 0.050 |
Why?
| | Peptide Elongation Factors | 1 | 2022 | 15 | 0.050 |
Why?
| | RNA Splice Sites | 1 | 2022 | 51 | 0.050 |
Why?
| | 5' Untranslated Regions | 1 | 2022 | 59 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2022 | 69 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 66 | 0.040 |
Why?
| | Serine | 1 | 2022 | 143 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 870 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 296 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2022 | 337 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2022 | 368 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 158 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 184 | 0.040 |
Why?
| | Pyrimidines | 1 | 2022 | 530 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2022 | 1132 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1767 | 0.030 |
Why?
| | Mice, SCID | 1 | 2018 | 369 | 0.030 |
Why?
| | Adult | 3 | 2025 | 40777 | 0.030 |
Why?
| | Genome, Human | 1 | 2020 | 420 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2018 | 886 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 613 | 0.030 |
Why?
| | Israel | 1 | 2016 | 46 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 919 | 0.030 |
Why?
| | Pakistan | 1 | 2016 | 79 | 0.030 |
Why?
| | India | 1 | 2016 | 213 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2018 | 452 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 253 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 934 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 454 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 1199 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2803 | 0.030 |
Why?
| | Haplotypes | 1 | 2016 | 499 | 0.030 |
Why?
| | Phosphorylation | 1 | 2018 | 1707 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8333 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 981 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2507 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1852 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2440 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1407 | 0.020 |
Why?
|
|
Davidson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|